A world-first clinical trial led by Australian researchers has shattered long-standing uncertainty over whether statins should be prescribed to healthy people aged over 70, revealing the common cholesterol-lowering drugs can dramatically cut the risk of heart attacks and strokes in this rapidly growing age group.
The decade-long study, involving almost 10,000 participants recruited through nearly 3,400 GPs across Australia, found that a daily statin reduced the chance of a first major cardiovascular event by 30% in otherwise healthy older adults. Put plainly, for every 37 people aged over 70 who took the medication daily for close to six years, one heart attack, stroke, or cardiac surgery was prevented.
The findings were published in the New England Journal of Medicine on Saturday and unveiled simultaneously at the European Society of Cardiology Congress in Germany, marking what researchers are calling the most rigorous evidence yet on a question medicine has sidestepped for decades.
A Missing Piece in the Prevention Puzzle
Statins are already routinely handed out to people under 75 who meet established risk thresholds, such as those with diabetes and high cholesterol, or to anyone who has already survived a major heart event, regardless of age.
What nobody knew with certainty was whether a daily statin was safe or genuinely beneficial for healthy septuagenarians and beyond, people who had never suffered a heart attack, stroke, or cardiac surgery, and who might live for another 15 or 20 years.
Adjunct Prof Mark Nelson of Monash University’s school of public health and preventive medicine, a co-author of the study, described it as a critical gap in the medical literature.
“Increasing age is the biggest risk factor for major cardiovascular events,” he said. “Our society is ageing, and the burden of disease is growing, so we had to find out if statins actually work as a prevention tool in this group.”
He pointed out that older adults have been routinely overlooked in pharmaceutical research stretching back 40 years, an era when heart disease was overwhelmingly a middle-aged smoker’s affliction and public health campaigns were rightly directed at preventing premature deaths in that demographic.
“Elderly populations may be sick, on multiple medications, and trialling drugs in that group was considered risky,” Nelson said. “But that left us flying blind.”
The Trial and What It Revealed
The Monash team deployed a randomised control design, the gold standard in medical research, splitting participants into two arms: one receiving a daily statin, the other a placebo. Anyone with a condition that might make the drug unsafe, anyone not living independently, or anyone who already required statins because of a prior heart event was excluded.
The results, published at the weekend, were unambiguous. The 30% reduction in first-time major cardiovascular events translates to tangible, life-altering prevention at the population level, said Prof James Chong, a cardiologist at Sydney’s Westmead Hospital.
“If this research leads to increased statin use globally, the absolute reduction of events can be significant,” Chong said. “One of the major changes that may result is more elderly patients having confidence to take long-term statins.”
But Chong sounded a note of caution. The trial population was almost exclusively white, with an average age of around 75. Whether the findings translate cleanly to more ethnically diverse populations, or to the very old, remains an open question requiring further investigation.
The Dementia Question and the Adherence Problem
One persistent shadow hanging over statins, particularly among older patients, has been the long-running claim that the drugs can cause cognitive decline and dementia, misinformation that has fuelled reluctance to take them.
That fear, said Prof Tom Marwick, a cardiologist at Hobart’s Royal Hospital, can now be largely put to rest. The Monash study tracked dementia rates across both trial arms and found no statistically significant difference between those who took statins and those who did not.
“This really closes the book on that, in large numbers,” Marwick said. He called the trial “well done, really important”.
Yet the research was not without its frustrations. More than 15% of participants in the active treatment group stopped taking their medication during the trial, a discontinuation rate that has implications for how the findings will translate into the messy reality of everyday clinical practice.
Marwick also flagged a sobering nuance. While major heart events fell sharply, the overall measure of disability-free survival was identical between those who took statins and those who took the placebo. In other words, the drug postponed cardiac catastrophes but did not, in the aggregate, extend life or its quality.
“We can reduce cardiovascular events, but the health burdens of ageing are less amenable,” he said.
Lead researcher Adjunct Prof Sophia Zoungas said the team now hoped the robust evidence would prompt a swift revision of treatment guidelines, giving clinicians across the world the green light to discuss statins with healthy older patients as a matter of course. She urged anyone over 70 to raise the question with their GP.
Why it Matters
With populations ageing across the developed world, the incidence of heart attacks and strokes among the over-70s is set to soar, straining health systems already creaking under the weight of chronic disease. The Monash trial hands clinicians the first hard evidence that statins work in this group, offering a cheap, well-understood, and widely available tool to prevent tens of thousands of premature deaths and disabling events each year. The challenge now is twofold: rewriting treatment guidelines to reflect the findings, and persuading older patients, many of them wary of decades of statin scare stories, to keep taking the pills.
